자가면역질환 치료 시장 : 질환별, 약제별, 지역별

Autoimmune Disease Treatment Market is estimated to be valued at USD 8.14 Bn in 2026 and is expected to reach USD 13.60 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.6% from 2026 to 2033.

The market is witnessing sustained growth primarily driven by the rising prevalence of autoimmune diseases, increasing diagnosis rates, growing adoption of biologic and targeted therapies, and continued advancements in immunomodulatory treatment approaches. Autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel diseases, systemic lupus erythematosus, autoimmune thyroid diseases, and type 1 diabetes often require prolonged or lifelong treatment, supporting recurring demand for pharmacological therapies.

The treatment landscape encompasses immunosuppressants, anti-inflammatory drugs, corticosteroids, nonsteroidal anti-inflammatory drugs, and other therapies, addressing both systemic and organ-specific autoimmune diseases. The market is increasingly transitioning from broad immune suppression toward more targeted therapeutic approaches directed at cytokines, antibodies, receptors, B-cell pathways, and other disease-specific immune mechanisms. This transition is expanding treatment options for patients who demonstrate inadequate responses to conventional corticosteroids and immunosuppressive therapies.

Advancements in targeted oral therapies, self-administered biologics, biosimilars, and emerging immune-reset approaches such as CAR-T cell therapy are further reshaping the treatment paradigm. These innovations are improving treatment specificity, convenience, and long-term disease management while broadening therapeutic options for patients with severe or treatment-refractory autoimmune conditions.

Market Dynamics

The market is gaining significant momentum owing to the increasing clinical burden of chronic autoimmune diseases and the growing requirement for long-term disease management. Conditions such as rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease, myasthenia gravis, and autoimmune thyroid disorders frequently require prolonged pharmacological intervention, thereby supporting sustained demand for immunosuppressants, corticosteroids, anti-inflammatory drugs, and targeted therapies. Diagnostic gaps also represent an important market factor, as delayed diagnosis can postpone initiation of appropriate treatment and increase the unmet therapeutic need.

The rapid development and adoption of targeted biologics and pathway-specific therapies is another major factor transforming the market. Treatment approaches are increasingly focusing on specific immune mediators rather than generalized immune suppression, thereby expanding options for patients inadequately controlled with traditional therapies. Continuous regulatory approvals of novel biologics, biosimilars, targeted oral therapies, and self-administered formulations are strengthening the availability of advanced treatment options across multiple autoimmune indications.

The market is also benefiting from increasing biopharmaceutical research activity, regulatory initiatives supporting biosimilar development, and growing interest in next-generation therapeutic modalities. Emerging approaches such as CAR-T cell therapy aim to achieve deeper immune-system resetting in selected severe autoimmune diseases, potentially shifting parts of the treatment landscape from continuous immunosuppression toward more durable disease control. At the same time, self-administered biologics and targeted oral therapies are increasing treatment convenience and supporting a gradual transition toward more patient-centric autoimmune disease management.

North America is expected to remain a major market owing to advanced specialty-care infrastructure, high adoption of biologics and targeted immunotherapies, strong pharmaceutical R&D activity, and rapid uptake of innovative treatments. Meanwhile, Asia Pacific is expected to witness comparatively faster growth, supported by expanding availability of biologics and biosimilars, increasing specialty-care infrastructure, domestic biopharmaceutical development, and broader regulatory approvals of targeted therapies.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Autoimmune Disease Treatment Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Active Biotech, GlaxoSmithKline plc, Eli Lilly and Company, AutoImmune Inc., Pfizer, Inc. AstraZeneca plc, Lupin Limited, 4SC AG, Amgen, Inc., and Bristol-Myers Squibb.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Autoimmune Disease Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Autoimmune Disease Treatment Market

Market Segmentation

• By Disease Type (Revenue, USD Bn, 2021-2033)
• Systemic
• Organ-specific
• By Drug Type (Revenue, USD Bn, 2021-2033)
• Immunosuppressant's
• Anti-Inflammatory Drugs
• Corticosteroids
• Nonsteroidal anti-inflammatory drugs
• Others
• Global Autoimmune Disease Treatment Market, By Region (Revenue, USD Bn, 2021-2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
• Johnson & Johnson
• Abbott Laboratories
• Hoffmann-La Roche Ltd.
• Active Biotech
• GlaxoSmithKline plc
• Eli Lilly and Company
• AutoImmune Inc.
• Pfizer, Inc.
• AstraZeneca plc
• Lupin Limited
• 4SC AG
• Amgen, Inc.
• Bristol-Myers Squibb

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Global Autoimmune Disease Treatment Market, By Disease Type, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Systemic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Organ-specific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Autoimmune Disease Treatment Market, By Drug Type, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Immunosuppressant's
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Anti-Inflammatory Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Nonsteroidal anti-inflammatory drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Autoimmune Disease Treatment Market, By Region, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • F. Hoffmann-La Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Active Biotech
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • AutoImmune Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • AstraZeneca plc
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Lupin Limited
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • 4SC AG
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Amgen, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Bristol-Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
• Analyst Views

8. Section

• References
• Research Methodology
• About Us